文献速递呼吸危重症与机械通气

右美托咪定与丙泊酚联合镇静的剂量相关90天死亡率:SPICE III二次队列分析

Dexmedetomidine and Propofol Sedation in Critically Ill Patients and Dose-associated 90-Day Mortality: A Secondary Cohort Analysis of a Randomized Controlled Trial (SPICE III).
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

该研究为SPICE III随机对照试验的二次队列分析,纳入1177例接受右美托咪定并补充丙泊酚的危重患者,按年龄(>65岁或≤65岁)分层。双分层分析显示,在年轻患者中,右美托咪定固定输注速率下增加丙泊酚至1.27 mg/kg/h与调整后死亡率降低相关,而增加右美托咪定速率则与死亡率升高相关。

要点

  • ≤65岁患者联合镇静时,优先增加丙泊酚剂量与90天死亡率降低相关。
  • ≤65岁患者增加右美托咪定输注速率与调整后死亡率升高相关。
  • 年轻患者达到相当镇静深度所需两种镇静剂剂量均显著高于老年患者。

核心结论

  • 在≤65岁接受右美托咪定与丙泊酚联合镇静的患者中,优先增加丙泊酚剂量与调整后90天死亡率降低相关,而增加右美托咪定可能与死亡率升高相关。

研究设计与样本

  • SPICE III随机对照试验的二次队列分析,纳入1177例随机接受右美托咪定并补充丙泊酚的危重患者,按年龄(>65岁或≤65岁)分层。

主要发现

  • 年轻患者(598/1177,50.8%)达到可比镇静深度时两种镇静剂剂量均显著高于老年患者。
  • 双分层分析中,右美托咪定固定输注速率0.54 μg/kg/h时,丙泊酚输注速率增至1.27 mg/kg/h与年轻患者调整后死亡率降低相关,老年患者无此关联。
  • 多变量回归显示,年轻患者中丙泊酚剂量增加与死亡率降低相关(HR 0.59;95%CI 0.43-0.78;P<0.0001)。
  • 年轻患者中右美托咪定输注速率增加与调整后死亡率升高相关(HR 1.30;95%CI 1.03-1.65;P=0.029)。

关键数值与推荐

  • 丙泊酚输注速率1.27 mg/kg/h联合右美托咪定0.54 μg/kg/h时,年轻患者调整后死亡率降低(HR 0.59;95%CI 0.43-0.78;P<0.0001)。
  • 年轻患者右美托咪定剂量增加与死亡率升高相关(HR 1.30;95%CI 1.03-1.65;P=0.029)。

临床怎么用

  • 对≤65岁接受右美托咪定与丙泊酚联合镇静的危重患者,可优先增加丙泊酚剂量而非右美托咪定剂量。
  • 需注意年龄对镇静剂剂量与死亡率关联的修饰作用,老年患者策略可能不同。

局限性

  • 为随机对照试验的二次队列分析,结果需进一步验证。
  • 仅纳入接受右美托咪定并补充丙泊酚的患者,结论不能推广至其他镇静方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The SPICE III (Sedation Practice in Intensive Care Evaluation) trial reported significant heterogeneity in mortality with dexmedetomidine treatment. Supplemental propofol was commonly used to achieve desirable sedation. Objectives: To quantify the association of different infusion rates of dexmedetomidine and propofol, given in combination, with mortality and to determine if this is modified by age. Methods: We included 1,177 patients randomized in SPICE III to receive dexmedetomidine and given supplemental propofol, stratified by age (>65 or ⩽65 yr). We used double stratification analysis to produce quartiles of steady infusion rates of dexmedetomidine while escalating propofol dose and vice versa. We used Cox proportional hazard and multivariable regression adjusted for relevant clinical variable to evaluate the association of sedative dose with 90-day mortality. Measurements and Main Results: Younger patients (598 of 1,177 [50.8%]) received significantly higher doses of both sedatives compared with older patients to achieve comparable sedation depth. On double stratification analysis, escalating infusion rates of propofol to 1.27 mg/kg/h at a steady dexmedetomidine infusion rate (0.54 μg/kg/h) was associated with reduced adjusted mortality in younger but not older patients. This was consistent with multivariable regression modeling (hazard ratio, 0.59; 95% confidence interval, 0.43-0.78; P < 0.0001) adjusted for baseline risk and interaction with dexmedetomidine dose. In contrast, among younger patients, using multivariable regression, escalating dexmedetomidine infusion rate was associated with increased adjusted mortality (hazard ratio, 1.30; 95% confidence interval, 1.03-1.65; P = 0.029). Conclusions: In patients ⩽65 years of age sedated with dexmedetomidine and propofol combination, preferentially increasing the dose of propofol was associated with decreased adjusted 90-day mortality. Conversely, increasing dexmedetomidine may be associated with increased mortality. Clinical trial registered with www.clinicaltrials.gov (NCT01728558).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Shehabi Y, Serpa Neto A, Bellomo R, et al. Dexmedetomidine and Propofol Sedation in Critically Ill Patients and Dose-associated 90-Day Mortality: A Secondary Cohort Analysis of a Randomized Controlled Trial (SPICE III). Am J Respir Crit Care Med. 2023. PMID: 36215171. doi:10.1164/rccm.202206-1208OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。